• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

ovarian cancer

Eli Lilly Lilly
Biotech

ESMO: Lilly ADC sees 79% ORR in competitive ovarian cancer space

The phase 1 data shed light on Lilly's chances of competing for a market targeted by rivals including AbbVie and Genmab.
Nick Paul Taylor Oct 24, 2026 2:30am
GSK ESMO

ESMO: GSK cancer R&D chief says data ‘reinforces belief’ in mo-rez

Oct 23, 2026 6:05pm
cancer cell split mitosis breast cancer metastasize

ESMO: Why Zentalis is already dreaming of launching WEE1 drug

Oct 23, 2026 10:15am
Genmab

Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere

Oct 5, 2026 4:14am
Gilead  Kite booth at AACR 2026

ASCO: Tubulis touts ovarian cancer data that attracted Gilead

May 30, 2026 9:36am
Magnifying glass focusing on womens health

OSE turns up the heat on ovarian cancer with phase 2 win

May 22, 2026 7:14am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings